yes, nice to see a bit of a rise. Still think this should be c£1 a share so anything below 80p is a steal IMHO. All the potential bad news is priced in and none of the growth potential. Also not just a retail stock and has no debts. Profit after tax expected to grow by 50% this year too on reasonably conservative forecasts
Summary below - says both cross selling and distribution. I did find this slightly strange as Leimo was only sold in Australia and has only be selling to existing customers for a few years now as IDP are essentially closing the brand down.Not sure if there is a link between thinning hair and PE but WTFDIK
Significant synergies with Leimo / Headmaster. Cross-selling and cross-border sales and distribution opportunities
Yes, good thinking Boon, I do remember him saying that but hadn't really thought of any potential upselling ££.
With this in mind - the May 2017 Prolong presentation issued by IDP mentioned cross selling opportunities between Prolong and Headmaster/Growlase . Hopefully with Prolong sales starting to increase (plus improved DTC strategy) this might kick in too, albeit from a much lower base.
RE: RNS TR-1: notification of major holdings16 Oct 2019 13:17
yep recent TR1 shows that Blackrock have sold a few. Previously they held over 5% of GKP now they are less than 5%. Think also need to notify at 3% level so assume they still hold a substantial amount. Notifications need to be made when major shareholders breach specific % of holdings - both up or down. A customer increasing holding is seen as a positive - a seller less so, however, sometimes these companies sale for non commercial reasons e.g. a switch in internal investment strategy or if a companies size is less than the investment criteria.
all the 68s are buys today, so it seems a little confidence is returning at these prices.
2020 look pretty conservative so a £2m profit will be c£1.5m after tax - at the current P/E of c10 (very low - FTSE average is 14) this is c105p a share - a 50% increase on todays price.
Also think DTC increase of 22% in 2019 has not been fully understood. Firstly c50% of IDP revenue comes from this route so this give company some protection from retail issues and also ensures cashflow remains healthy. Also there were issues in H1 last year so a 22% increase over the year means that H2 could have been c30%. Transferring these lessons learned into H1 this year will clearly increase revenues too, and from a lower base. Also we now have c600k database of customers now (up from 400k year before). All these people will have email addresses etc and will have already bought IDP products. It is a lot easier and cheaper to get repeat sales from existing customers than new customers. Finally these DTC improvements are already being rolled out into the US and Australia and could be used across other brands too - Roots has over 29k facebook followers etc
Hopefully this progress will be reflected in a positive update/statement at next month's AGM
well I'm in STX which has recently gone through phase 3 and FDA approval.
Bought at 45p - steady rise up during phase 3 and then approval to just over £1. It went up to £1.20 and then had a wobble just before FDA announcement so dipped back to 1.05. On approval went up to £1.80 overnight, where it is now. Expecting a US partner deal anytime now which should push it to £2.50 ish range.
Obvious a different product but I would say 50% increase with phase 3 approval and another 50% with FDA. So conservatively 30p and then 45p. Wouldn't be surprised to see 50p this time next year IMHO
It was 0.15 but has had 2 massive dilutions since - just saying. Probably 0.06 equivalent, however, we are in a much better position now with the additional drill results etc. Definitely see 0.1 coming
Got the eye cream and the serum. Only be using a few days but quite impressed. Packaging is very impressive and looks very professional. Both have a unique dispenser too - so no need to squeeze bottle.
The creams are light and easy to apply. Not sure if they will reduce the sign of ageing as they claim, but still early days!
although C+L is growing I was slightly underwhelmed at the c£200k rev from last year particularly as we have been told that xmas bundles sold extremely well (according to CEO). However, I have just clarified with company that since April C+L is in all 450 Priceline stores (I knew it was added to Priceline, assume It was a limited number of stores). This time last year I think it was in c50 Myers stores and it has recently added c30 in NZ too. However, the 450 Priceline stores leading up to xmas could be a significant revenue generator for IDP.
UK roll out should of course make a massive boost, especially if they get a retail tie in in addition to DTC - this is still planned for H2 2020.
FinnCap has £400k rev for C+L in 2020 - I'm guessing this doesn't include any UK contribution. As with Prolong these numbers look conservative IMHO